Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany.
Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
Strahlenther Onkol. 2022 Oct;198(10):884-891. doi: 10.1007/s00066-022-01950-1. Epub 2022 May 11.
Whole-brain radiotherapy (WBRT) used to be standard of care for patients suffering from melanoma brain metastases (MBM) and may still be applicable in selected cases. Deterioration of neurocognitive function (NCF) is commonly seen during and after WBRT. Knowledge on long-term effects in melanoma patients is limited due to short survival rates. With the introduction of immune checkpoint inhibitors, patients may experience ongoing disease control, emphasizing the need for paying more attention to potential long-term adverse effects.
In this single-center study, we identified in a period of 11 years all long-term survivors of MBM who received WBRT at least 1 year prior to inclusion. NCF was assessed by Neuropsychological Assessment Battery (NAB) screening and detailed neurological exam; confounders were documented.
Eight patients (median age 55 years) could be identified with a median follow-up of 5.4 years after WBRT. Six patients reported no subjective neurological impairment. NAB screening revealed an average-range score in 5/8 patients. In 3/8 patients a NAB score below average was obtained, correlating with subjective memory deficits in 2 patients. In these patients, limited performance shown in modalities like memory function, attention, and spatial abilities may be considerably attributed to metastasis localization itself. Six out of 8 patients were able to return to their previous work.
Five of 8 long-term survivors with MBM after WBRT experienced little to no restriction in everyday activities. In 3 out of 8 patients, cognitive decline was primarily explained by localization of the metastases in functionally relevant areas of the brain. The results of our small patient cohort do not support general avoidance of WBRT for treatment of brain metastases. However, long-term studies including pretreatment NCF tests are needed to fully analyze the long-term neurocognitive effects of WBRT.
全脑放疗(WBRT)曾经是治疗黑色素瘤脑转移(MBM)患者的标准治疗方法,在某些情况下仍可能适用。在 WBRT 期间和之后,神经认知功能(NCF)通常会恶化。由于黑色素瘤患者的生存率较短,因此对其长期影响的了解有限。随着免疫检查点抑制剂的引入,患者可能会持续控制疾病,这强调了需要更加关注潜在的长期不良反应。
在这项单中心研究中,我们在 11 年内确定了所有至少在纳入前 1 年接受过 WBRT 的 MBM 长期幸存者。通过神经心理评估电池(NAB)筛查和详细的神经检查评估 NCF;记录混杂因素。
在 WBRT 后随访 5.4 年的中位数时间,我们确定了 8 名患者(中位年龄 55 岁)。6 名患者报告没有主观神经功能障碍。NAB 筛查显示 8 名患者中有 5 名平均水平的分数。在 8 名患者中有 3 名获得低于平均水平的 NAB 分数,其中 2 名患者与主观记忆缺陷相关。在这些患者中,记忆功能、注意力和空间能力等模式下的有限表现可能主要归因于转移的定位本身。8 名患者中有 6 名能够恢复到之前的工作。
在接受 WBRT 治疗的 8 名 MBM 长期幸存者中,有 5 名患者在日常生活中几乎没有受到限制。在 8 名患者中有 3 名患者,认知能力下降主要是由于转移位于大脑功能相关区域。我们的小患者队列的结果不支持普遍避免 WBRT 治疗脑转移。然而,需要进行长期研究,包括治疗前 NCF 测试,以充分分析 WBRT 的长期神经认知影响。